Highlights

  • Ryoncil generated US$115.2 million of net product Revenue in FY26, while total group revenue reached US$120.3 million.
  • Net loss narrowed to US$57.5 million from US$102.1 million, while second-half operating cash outflow fell to US$13.4 million.
  • Cash stood at US$103 million at 30 June 2026, alongside new and existing Debt facilities that remain relevant to the funding profile.
  • Adult graft-versus-host disease, chronic low back pain, heart failure and muscular dystrophy programmes remain important clinical milestones.
  • Near-term watch points include quarterly Ryoncil sales, trial site activation and regulatory progress across the pipeline.

Mesoblast Limited (ASX:MSB) develops allogeneic cell medicines made from donor-derived mesenchymal cells. FY26 was its first full year of United States sales for Ryoncil, or remestemcel-L, approved for children with steroid-refractory acute graft-versus-host disease. The result established a material commercial revenue base while clinical execution and financing remain central to the outlook.

Ryoncil Creates a New Revenue Base

FY26 total revenue was US$120.3 million, compared with US$17.2 million a year earlier. Ryoncil accounted for US$115.2 million of net product revenue. The June 2026 quarter contributed US$36 million, while the second half generated US$66.5 million, indicating continued commercial uptake through the year.

Gross profit was US$103.6 million, or US$109.7 million before amortisation. The source does not provide a detailed cost-of-goods breakdown, so the reported figures are the appropriate reference.

Losses and Cash Burn Narrow

Mesoblast remained loss-making in FY26, but the net loss narrowed 44% to US$57.5 million from US$102.1 million. Net operating cash outflow was US$43.8 million for the year and US$13.4 million in the second half, showing a lower rate of cash consumption as sales grew.

Cash was US$103 million at 30 June 2026. The company drew US$50 million from an existing Facility to repay maturing debt and later reported securing a new five-year US$125 million Credit facility. Debt therefore remains part of the Capital Structure even as commercial revenue reduces dependence on Equity funding.

Clinical Pipeline Remains a Major Value Driver

Further growth depends on clinical and regulatory progress beyond the current paediatric Ryoncil indication. Mesoblast is running a registrational adult trial in steroid-refractory acute graft-versus-host disease, with up to 40 US sites expected to open. The registrational study remains the key test.

Rexlemestrocel-L for chronic low back pain is in a pivotal Phase 3 trial, with more than 300 patients treated and top-line results expected around mid-2027. Mesoblast also received a Biologics License Application filing number in heart failure and clearance for a registrational Ryoncil trial in muscular dystrophy.

Key Risks and Watch Points

The principal risks remain clinical outcomes, regulatory timing, Manufacturing scale-up, reimbursement and product adoption. Revenue is concentrated in one product and one country. The company has not provided explicit revenue guidance, so reported quarterly sales remain the clearest measure of progress.

Key Insights

FY26 established a commercial base, with Ryoncil generating most group revenue and helping narrow losses and cash burn. Mesoblast still relies on continued adoption, funding discipline and clinical execution. Key evidence points are quarterly Ryoncil sales, adult trial progress, heart-failure regulatory updates and the mid-2027 chronic low back pain readout.